ZA201701800B - Solid state forms of fused heteroaromatic pyrrolidinones - Google Patents
Solid state forms of fused heteroaromatic pyrrolidinonesInfo
- Publication number
- ZA201701800B ZA201701800B ZA2017/01800A ZA201701800A ZA201701800B ZA 201701800 B ZA201701800 B ZA 201701800B ZA 2017/01800 A ZA2017/01800 A ZA 2017/01800A ZA 201701800 A ZA201701800 A ZA 201701800A ZA 201701800 B ZA201701800 B ZA 201701800B
- Authority
- ZA
- South Africa
- Prior art keywords
- solid state
- state forms
- fused heteroaromatic
- pyrrolidinones
- heteroaromatic pyrrolidinones
- Prior art date
Links
- -1 heteroaromatic pyrrolidinones Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093564P | 2014-12-18 | 2014-12-18 | |
| US201562115223P | 2015-02-12 | 2015-02-12 | |
| US201562180222P | 2015-06-16 | 2015-06-16 | |
| PCT/IB2015/002489 WO2016097862A2 (en) | 2014-12-18 | 2015-12-17 | Solid state forms of fused heteroaromatic pyrrolidinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201701800B true ZA201701800B (en) | 2020-05-27 |
Family
ID=55299676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/01800A ZA201701800B (en) | 2014-12-18 | 2017-03-13 | Solid state forms of fused heteroaromatic pyrrolidinones |
Country Status (29)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120632C2 (uk) * | 2014-12-18 | 2020-01-10 | Такеда Фармасьютікал Компані Лімітед | Тверді форми конденсованих гетероароматичних піролідинонів |
| WO2018013239A1 (en) * | 2016-07-13 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| JP2020537678A (ja) | 2017-10-19 | 2020-12-24 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用 |
| WO2019088039A1 (en) | 2017-10-30 | 2019-05-09 | Takeda Pharmaceutical Company Limited | Treatment of acute myeloid leukemia |
| JP7472138B2 (ja) * | 2018-12-14 | 2024-04-22 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｓｙｋ阻害剤の塩及びその結晶形 |
| CN113453680A (zh) | 2019-02-07 | 2021-09-28 | 詹森生物科技公司 | 二氢乳清酸脱氢酶抑制剂 |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| ES2970180T3 (es) | 2019-10-10 | 2024-05-27 | Janssen Biotech Inc | Inhibidores de la dihidroorotato deshidrogenasa bi-arilo |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| WO2022074534A1 (en) | 2020-10-05 | 2022-04-14 | Janssen Biotech, Inc. | Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents |
| WO2022127753A1 (zh) * | 2020-12-18 | 2022-06-23 | 山东轩竹医药科技有限公司 | 稠环类AhR抑制剂 |
| CN117337180A (zh) | 2021-05-11 | 2024-01-02 | 詹森药业有限公司 | 组合疗法 |
| AU2022274071A1 (en) | 2021-05-11 | 2024-01-04 | Janssen Pharmaceutica Nv | Combination therapies |
| WO2024114666A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4626426A1 (en) | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960372B1 (en) * | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| US9181255B2 (en) | 2009-12-23 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as SYK inhibitors |
| WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| TW201625263A (zh) * | 2014-09-24 | 2016-07-16 | 千禧製藥公司 | 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療 |
| UA120632C2 (uk) * | 2014-12-18 | 2020-01-10 | Такеда Фармасьютікал Компані Лімітед | Тверді форми конденсованих гетероароматичних піролідинонів |
-
2015
- 2015-12-17 UA UAA201707489A patent/UA120632C2/uk unknown
- 2015-12-17 US US14/973,180 patent/US10676473B2/en active Active
- 2015-12-17 CR CR20170249A patent/CR20170249A/es unknown
- 2015-12-17 CN CN201580068971.2A patent/CN107108609B/zh active Active
- 2015-12-17 PE PE2017000944A patent/PE20171179A1/es unknown
- 2015-12-17 BR BR112017013149-8A patent/BR112017013149B1/pt not_active IP Right Cessation
- 2015-12-17 TN TN2017000080A patent/TN2017000080A1/en unknown
- 2015-12-17 MY MYPI2017702209A patent/MY199935A/en unknown
- 2015-12-17 NZ NZ732371A patent/NZ732371A/en not_active IP Right Cessation
- 2015-12-17 SG SG11201701911QA patent/SG11201701911QA/en unknown
- 2015-12-17 WO PCT/IB2015/002489 patent/WO2016097862A2/en not_active Ceased
- 2015-12-17 DK DK15831150.6T patent/DK3233857T3/da active
- 2015-12-17 EP EP20156863.1A patent/EP3677582B1/en active Active
- 2015-12-17 EA EA201791369A patent/EA032291B1/ru unknown
- 2015-12-17 CA CA2970864A patent/CA2970864C/en active Active
- 2015-12-17 MX MX2017007162A patent/MX373586B/es active IP Right Grant
- 2015-12-17 ES ES15831150T patent/ES2788454T3/es active Active
- 2015-12-17 AU AU2015365580A patent/AU2015365580B2/en active Active
- 2015-12-17 JP JP2017532678A patent/JP6778195B2/ja active Active
- 2015-12-17 EP EP15831150.6A patent/EP3233857B1/en active Active
- 2015-12-17 GE GEAP201514545A patent/GEP20197050B/en unknown
- 2015-12-17 KR KR1020177019929A patent/KR102037502B1/ko active Active
- 2015-12-17 PL PL15831150T patent/PL3233857T3/pl unknown
-
2017
- 2017-03-13 ZA ZA2017/01800A patent/ZA201701800B/en unknown
- 2017-05-31 DO DO2017000130A patent/DOP2017000130A/es unknown
- 2017-06-15 CL CL2017001561A patent/CL2017001561A1/es unknown
- 2017-06-15 IL IL252941A patent/IL252941B/en active IP Right Grant
- 2017-06-15 CO CONC2017/0005910A patent/CO2017005910A2/es unknown
- 2017-06-15 PH PH12017501123A patent/PH12017501123A1/en unknown
- 2017-06-16 EC ECIEPI201738100A patent/ECSP17038100A/es unknown
-
2020
- 2020-04-30 JP JP2020080282A patent/JP6974534B2/ja active Active
- 2020-05-08 US US16/870,653 patent/US11352355B2/en active Active
-
2021
- 2021-11-04 JP JP2021180105A patent/JP2022017477A/ja active Pending
-
2022
- 2022-12-23 US US18/088,286 patent/US20230348461A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252941A0 (en) | Solid state forms of conjugated heteroaromatic pyrrolidinones | |
| IL258180B (en) | Heterocyclic compounds and their uses | |
| IL246838A0 (en) | A fused heterocyclic compound | |
| IL248312A0 (en) | suspension element | |
| SG11201605417QA (en) | Heterocyclic compounds | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| EP3133075A4 (en) | Fused heterocyclic compound | |
| HU4602U (en) | Set of saggar assembly | |
| SI3845221T1 (sl) | Trdne oblike sofosbuvirja | |
| IL265628A (en) | Solid state forms of valbenazine | |
| GB201411526D0 (en) | Powder | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| ZA201606077B (en) | Pyrazines modulators of gpr6 | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| ZA201606598B (en) | Novel fused imidazobenzothiazole compounds | |
| HU4603U (en) | Set of saggar assembly | |
| IL246569A0 (en) | Solid forms of tenofovir | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| IL254666A0 (en) | Crystalline forms of Aldecalcitol | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| GB2557903B (en) | Suspension element | |
| GB201421944D0 (en) | Suspension bridges | |
| GB201421938D0 (en) | Suspension bridges | |
| GB201421941D0 (en) | Suspension bridges | |
| GB201418230D0 (en) | Construction of surfaces |